Trial Profile
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI 136 Administered Orally to Healthy Young and Healthy Elderly Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs GSI 136 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 07 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Aug 2008 New trial record.